Pfizer Is transferring past Covid. Why Its inventory Is a buy.

Pfizer in all probability did larger than every fully different agency to assist the world normalize from the pandemic, and it reaped a monetary windfall from its twin Covid-19 franchise—the very best-promoting vaccine and the main remedy, Paxlovid.

The world, nonetheless, has stopped worrying about Covid—and Pfizer (ticker: PFE) is paying the worth. The gross sales of its two Covid blockbusters might decline over 60% in 2023, after producing a mixed $fifty seven billion in income all by way of 2022. And there might even be appreciable uncertainty about demand for every inside the approaching years.

Sourcelink

Post a Comment

0 Comments